LIPA and metabolic syndrome: The progressive pathogenesis of LAL-D has been extensively studied in LAL-deficient (Lal−/−) mice, which develop hepatosplenomegaly, liver steatosis, and dyslipidemia [23–25], similar to the symptoms observed in LAL-D patients.